This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves - Summary - MDSpire

This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves

  • May 26, 2026

Share

Objective:

To summarize recent developments in biopharmaceuticals, including clinical trial results and regulatory updates.

Key Findings:
  • Sac-TMT met primary endpoints in endometrial cancer.
  • MB097 showed safety and efficacy in advanced melanoma.
  • Ligufalimab demonstrated a survival signal in AML.
  • Regeneron's melanoma trial did not meet primary endpoint.
  • Dual-pressure CHO system improved antibody productivity.
  • Bispecific antibody architecture impacts manufacturability.
  • High-concentration mAbs present new manufacturing challenges.
  • FDA guidance aims to enhance pregnancy safety data collection.
Interpretation:

Limitations:
Conclusion:

Original Source(s)

This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves

  • May 26, 2026

Related Content

Beyond Nodule Detection: AI, Chest CT, and a Vision for Population Health

Lung cancer resulted in 1.8 million deaths globally in 2022 and remains the leading cause of cancer-related mortality worldwide. Low-dose CT screening has been shown to reduce lung cancer mortality, a...

2026 NCCN Clinical Practice Guidelines in Oncology®: Key Updates Across Tumor Types

The National Comprehensive Cancer Network® (NCCN®) first introduced the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, initially covering eight tumor types. Three decades la...

Preclinical Study in Mice Addresses a Question: Should RAS Inhibitors Be Given Preemptively?

With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer, the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research ...